New eye drug tiespectus takes on standard treatment for wet AMD
NCT ID NCT07496567
First seen Apr 14, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tests a new medicine called tiespectus (also known as MK-8748 or EYE201) against the standard treatment aflibercept for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 960 people with untreated wet AMD will receive injections into the eye to see if tiespectus works as well as aflibercept at improving vision over one year. The goal is to offer another treatment option for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.